 SOUTH PLAINFIELD, N.J., May 17, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid decarboxylase deficiency AADC-d. 